Severe, refractory, non-malignant type I cryoglobulinemia treated with alemtuzumab.
A 41 year old female with type I cryoglobulinemia, refractory to methylprednisolone, rituximab, and cyclophosphamide complicated by a rising serum viscosity was treated with alemtuzumab. After a cumulative dose of 1,085 mg of alemtuzumab, her serum viscosity decreased to normal. Treatment toxicity was limited to fungal esophagitis responsive to topical therapy. This case demonstrates the potential use of alemtuzumab in the treatment of refractory cryoglobulinemia.
Chu
David
D
Stony Brook University Medical Center, SUNY Stony Brook, HSC, Level 17, Rm 080, Stony Brook, NY 11794-8174, USA.
Stevens
Michelle
M
Gladstone
Douglas Edward
DE
D000328:Adult; D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001809:Blood Viscosity / Q000187:drug effects; D003449:Cryoglobulinemia / Q000175:diagnosis / Q000188:drug therapy*; D018432:Drug Resistance, Multiple / Q000187:drug effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D012074:Remission Induction; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000074323:Alemtuzumab